{"config": {"lang": ["en"], "separator": "[\\s\\-]+", "pipeline": ["stopWordFilter"]}, "docs": [{"location": "tags/", "title": "Tags", "text": ""}, {"location": "tags/#arteriolosclerosis", "title": "Arteriolosclerosis", "text": "<ul> <li>Classifications</li> </ul>"}, {"location": "USMLE/Questions/", "title": "Questions", "text": "<ol> <li>AVNRT</li> <li>cardiomyopathy associated with a widely disseminated adenocarcinoma of unknown primary origin</li> <li>Mitral stenosis</li> <li>Atrial tachycardia with block</li> </ol>"}, {"location": "USMLE/%E5%8D%95%E6%8A%97%E8%AE%B0%E5%BF%86/", "title": "\u5355\u6297\u8bb0\u5fc6", "text": "<p>\u987a\u4e00\u904dFA\u53d1\u73b0\u5bf9\u5355\u6297\u7684\u540d\u5b57\uff0c\u8d8a\u6765\u8d8a\u6a21\u7cca\uff0c\u4e3a\u4ec0\u4e48\u4f1a\u6709\u8fd9\u4e48\u53cd\u4eba\u7c7b\u7684\u836f\u540d\u5462\uff1f</p> <p>\u4e3a\u5565\u4e00\u5806\u4e00\u5806\u7684\u51fa\u73b0\uff0c\u5c31\u4e0d\u80fd\u4e00\u6837\u53ea\u6709\u4e00\u4e2a\u5417\uff1f</p> <p>\u4e3a\u4e86\u89e3\u6551\u548c\u6211\u4e00\u6837\u7684\u5b66\u6e23\uff0c\u8bb0\u6027\u5dee\u661f\u4eba</p> <p>\u5728\u6b64\u6574\u7406\u4e86FA\u4e0a\u7684\u6240\u6709\u5355\u6297\uff0c\u5728\u6b64\u611f\u8c22\u70ed\u5fc3\u5c0f\u4f19\u4f34\u2003</p> <p>@Dr.Why</p> <p>, Ishmael, \u674e\u4e39\u533b\u751f\u7684\u8d21\u732e\uff01\u56fe\u7247\u5747\u6765\u81ea\u7f51\u7edc\uff0c\u4fb5\u6743\u5220\u9664\uff01</p> <p>\u805a\u96c6\u591a\u4f4d\u5c0f\u4f19\u4f34\u7684\u667a\u6167\uff0c\u6c47\u96c6\u6210\u6b64\u7bc7\uff0c\u5e0c\u671b\u80fd\u5e2e\u52a9\u5927\u5bb6\u8bb0\u5fc6\uff01</p> <p>\u4e5f\u6b22\u8fce\u5927\u5bb6\u6709\u66f4\u597d\u7684\u8bb0\u5fc6\u65b9\u6cd5\u7559\u8a00\uff0c\u6211\u4eec\u4e00\u8d77\u4e92\u76f8\u5b66\u4e60\u8fdb\u6b65\uff01</p> <p>\u52a0\u6cb9\uff0c\u4e89\u53d6\u4e00\u6b21\u62ff\u4e0b\uff01</p> <p>\u8a00\u5f52\u6b63\u4f20</p> <p>1.Adalimumab, certolizumab, golimumab, infliximab</p> <p>Anti-TNF-\u03b1 monoclonal antibody</p> <p>Add certain goal inflicting TNF-\u03b1</p> <p>Etanercept intercepts TNF</p> <p>\u6765\u81eadirtymedicine\uff0c\u8fd9\u4e5f\u662f\u6cb9\u7ba1\u4e0a\u7684\u4e00\u4e2a\u5927\u4f6c\uff0c\u63a8\u8350\u53bb\u56f4\u89c2</p> <ol> <li>Alemtuzumab</li> </ol> <p>anti-CD52</p> <p>AL\u5f00\u5934\u7684\u5355\u6297\u53ea\u6709\u5b83</p> <p>\u54ce(A)\uff0c\u674e(l)\u548f\u6ca1(m)\u4e86</p> <p>\u4ed6\u7684\u738b\u724c\u8282\u76ee\u2013\u5e78\u8fd052</p> <p></p> <p>\u6cbb\u7597\uff1aCLL, multiple sclerosis\uff0cchronic lymphocytic leukemia</p> <p>against VEGF</p> <ol> <li>Bevacizumab</li> </ol> <p>inhibits Blood Vessel formation</p> <p>Solid tumors (colorectal cancer, renal cell carcinoma), wet age-related macular degeneration</p> <ol> <li>Ranibizumab</li> </ol> <p>Bizu\u4e24\u4e2a\u773c\u73e0 \u6765\u81eaDr.Why</p> <p>\u5bf9\u5e94Age-related macular degeneration</p> <p>\u4e5f\u53ef\u4ee5\u6cbb\u7597\u89c6\u7f51\u819c\u75c5\u53d8</p> <p>\u552f\u4e00\u9488\u5bf9\u8865\u4f53\u7684</p> <ol> <li>Eculizumab</li> </ol> <p>Complement protein C5</p> <p>E\u662f\u7b2c\u4e94\u4e2a\u5b57\u6bcd\uff0c\u6240\u4ee5\u5bf9\u5e94C5</p> <p>\u6cbb\u7597\uff1aParoxysmal nocturnal hemoglobinuria</p> <p>\u957f\u5f97\u7279\u522b\u5947\u602a\u7684</p> <ol> <li>Bortezomib, carfilzomib</li> </ol> <p>FA\u4e0amib\u7ed3\u5c3e\u7684\u5c31\u8fd9\u4e24\u4e2a</p> <p>\u4ed6\u4eec\u6709M\u503e\u5411</p> <p>Proteasome inhibitor</p> <p>induce arrest at G2-M phase and apoptosis</p> <p>Multiple myeloma, mantle cell lymphoma</p> <p>Side effect: Peripheral neuropathy, herpes zoster reactivation</p> <p>7.Palbociclib</p> <p>-ciclib</p> <p>Cyclin-dependent kinase inhibitor</p> <p>medication for the treatment of HR-positive and HER2-negative breast cancer</p> <p>\u8e22\u4f60\u4e0d</p> <p>tyrosine kinase inhibitor</p> <p>8.Erlotinib</p> <p>EGFR tyrosine kinase inhibitor</p> <p>Non-small cell lung cancer</p> <p>Rash, diarrhea</p> <p>9.Imatinib, dasatinib, nilotinib</p> <p>Tyrosine kinase inhibitors of bcr-abl</p> <p>Philadelphia chromosome fusion gene in CML</p> <p>c-kit (common in GI stromal tumors)</p> <ol> <li>\u7279\u6b8aRuxolitinib</li> </ol> <p>JAK1/2 inhibitor</p> <p>JAK1\u662fTyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway</p> <p>Use: Polycythemia vera</p> <p>Jack and Rose</p> <p></p> <p>\u524d\u65b9\u9ad8\u80fd\u9884\u8b66</p> <p>\u559c\u6b22LU\u7684PD</p> <p>Lumab\u5c31\u8fd9\u51e0\u4e2a</p> <p>\u603b\u4f53\u53e3\u8bc0\uff1aNP\uff0cADA, \u6765\u81ea\u674e\u4e39\u5927\u592b\uff0c\u7a0d\u7a0d\u6539\u826f\u52a0\u5165\u6545\u4e8b</p> <ol> <li>Nivolumab, pembrolizumab</li> </ol> <p>Inhibit PD-1</p> <p>\u559c\u6b22lu\u548cNP\u7684PD \uff08project director,\u53c2\u8003\u7f57\u5fd7\u7965bro\uff0c\u4ed6\u5f53\u8fc7\u9009\u79c0\u8282\u76ee\u5bfc\u5e08\uff09</p> <p></p> <p>12.Atezolizumab, durvalumab, avelumab</p> <p>Inhibit PD-L1</p> <p>\u591a\u4e86\u4e2aL\uff0c\u66f4\u9ad8Level\uff0c\u6240\u4ee5\u662f\u5bf9\u5e94\u4e09\u4e2a\u836f\u7269ADA</p> <p>\u6765\u51e0\u4e2a\u7b80\u5355\u7684\u5e73\u590d\u4e00\u4e0b</p> <ol> <li>Rituximab</li> </ol> <p>against CD20</p> <p>which is found on most B-cell neoplasms</p> <p>\u4ece\u4e00\u5f00\u59cb\u505a\u9898\u5c31\u4f1a\u9047\u5230\u7684</p> <ol> <li>Palivizumab\uff0c-vi-/-v-</li> </ol> <p>\u6297\u75c5\u6bd2</p> <p>RSV F protein</p> <p>15.Denosumab</p> <p>\u5bf9\u5e94RANKL</p> <p>\u8fd9\u4e2a\u6bd4\u8f83\u7279\u522b\uff0c\u9aa8\u79d1\u7684\uff0c\u4e00\u822c\u4e0d\u4f1a\u5f04\u9519</p> <p>\u800c\u4e14-S-\u4ee3\u8868bone\uff0cFA\u540c\u7c7b\u5355\u6297\u91cc\u53ea\u6709\u5b83</p> <p>16.PCSK9 inhibitor</p> <p>PC=\u7834\u4ea7\uff0cPC\u53ea\u80fd\u54ed\u4e86cry=c\uff0c\u653e\u5fc3\u6ca1\u6709Kumab\u7684\u836f\u7269\uff0c\u6240\u4ee5\u53ea\u6709cumab</p> <p>Alirocumab, evolocumab</p> <p>Myalgias, delirium,dementia, other neurocognitive effects</p> <p>\u54ed\u5f97\u50cf\u4e2a\u50bb\u5b50\uff08\u795e\u7ecf\u75c7\u72b6\uff09</p> <p>17.Cetuximab, panitumumab</p> <p>Monoclonal antibodies against EGFR</p> <p>\u7b2c\u4e00\u79cd\uff1aCe\uff0c\u7b56\uff0c\u6e56\u5357\u8bdd\u8c03\u4f83</p> <p>Pan\uff0c\u76d8\uff0c\u4ee3\u8868\u6536\u62fe\u201d\u3001\u201c\u5bf9\u4ed8\uff0c\u76d8\u5b83</p> <p>\u4e24\u4e2a\u90fd\u662f\u6076\u641e\uff08eg\uff09\uff0c\u6240\u4ee5\u5bf9\u5e94EGFR</p> <p>\u7b2c\u4e8c\u79cd\uff1aEGFR\u4e00\u4e2a\u6cd5\u56fd\u516c\u53f8 Cetuximab\u7c7b\u4f3c\u96ea\u94c1\u9f99\uff0ccitreon, \u6b63\u597d\u662f\u6cd5\u56fd\u7684\u516c\u53f8 \u6765\u81eaDr.why</p> <p>panitumumab</p> <p>penny to mum\uff0c\u7ed9\u5988\u5988\u94b1\u6c42\u5988\u5988\u522b\u6253\uff08\u8868\u76ae\uff09</p> <p>\u7b2c\u4e09\u79cd\uff1aEGFR\uff0c\u4e00\u4e2a\u6cd5\u56fd\u4eba\uff0cCetuxi\u5438\u5410\u5438\uff08\u96ea\u8304\uff09\u6765\u81eaDr.why</p> <p>Stage IV colorectal cancer (wild-type KRAS), head and neck cancer</p> <p>Rash, elevated LFTs, diarrhea</p> <p>18.Trastuzumab</p> <p>Tu,\u5bf9\u5e942\uff0cHER-2</p> <p>Monoclonal antibody against HER-2 (c-erbB2), a tyrosine kinase receptor. Helps kill cancer cells that overexpress HER-2 through inhibition of HER-2 initiated cellular signaling and antibody dependent cytotoxicity.</p> <p>Kinu\u662f\u78e8\u5496\u5561\u8c46\u7684\u673a\u5668\uff0c\u78e8\u51fa\u4e00\u5806\u788e\u5c51=\u725b\u76ae\u7663 \u6765\u81eaDr.Why</p> <p>19.Ixekizumab, secukinumab</p> <p>IL-17A</p> <p>IX=9\uff0c\u52a0\u4e0a\u540e\u9762\u516b\u4e2a\u5b57\u6bcd\uff0c\u7b49\u4e8e17\uff0csec=\u7b2c\u4e8c\u4e2a\uff0c\u8ddf\u5728IX\u5927\u54e5\u540e\u9762\u4e5f\u662f\u5bf9\u4ed817\u7684 \uff08\u5c31\u662f\u8ddf\u7740Ixekizumab\u6df7\u4e2a\u773c\u719f\uff09</p> <p>Psoriasis, psoriatic arthritis</p> <p>20.ustekinumab</p> <p>IL-12/IL-23</p> <p>Psoriasis, psoriatic arthritis</p> <p>\u4e00\u517111\u4e2a\u5b57\u6bcd\uff0c\u52a0\u4e0a\u7f8e\u56fd12\u4e2a\u5dde\uff0c\u6240\u4ee5\u662f23</p> <p>21.Natalizumab</p> <p>a4-integrin</p> <p>ta= tetragon a\uff0c\u56db\u4e2aa\uff0c\u6240\u4ee5\u5bf9\u5e94a4-integrin</p> <p>22.Abciximab</p> <p>\u5fc3\u8840\u7ba1\u7cfb\u7edfcardiovascular\u3002example:-cixumab/-cumab</p> <p>Platelet glycoproteins IIb/IIIa</p> <p>23.Omalizumab</p> <p>IgE</p> <p>Li \u5bf9\u5e94\u8eab\u4efd\uff0cM\u7ffb\u8f6c\u4e00\u4e0b\u5c31\u662fE</p> <p>24.Dabrafenib, vemurafenib</p> <p>Small molecule inhibitors of BRAF oncogene \u2295 melanoma. VEmuRAF-enib is for V600Emutated BRAF inhibition. Often co-administered with MEK inhibitors (eg, trametinib).</p> <p>Metastatic melanoma</p> <ol> <li>Mepolizumab, reslizumab\u2014against IL-5</li> </ol> <p></p> <p>hive with eye - IL -5 map - mepolizumab raygun - reslizumab belt - Benralizumab \u2014against IL-5 receptor \u03b1</p> <p>IL\u8868\u660e\u8eab\u4efd\uff0c\u662f\u514d\u75ab\u76f8\u5173\u7684\uff0c5= \u6211 = \u672c\u7f8e\u4eba Ben\uff0cMe\uff08i\uff09\uff0cRe\uff08N\uff09</p> <p>26.ipilimumab (anti-CTLA-4 antibody) \u6765\u81eaDr.Why</p> <p>1\uff09\u4e00\u5339\u5389\u5bb3\u7684\u6bcd\u9a6cipilimumab\u7528\u56db\u6761\u817f\u4ecect\u8dd1\u5230LA</p> <p>2\uff09\u6625\u5929\uff08CT\uff09\u7684LA\uff0c\u6709\u4e00\u5339\u6bcd\u9a6c\uff0c\u56db\u6761\u817f</p> <p>3\uff09\u8fd9\u56db\u4e2a\u5b57\u6bcd\uff0c\u4e00\u5171\u6709\u56db\u4e2a\u76f4\u7ebf\uff0cline-4\uff0cL-4\uff0c\u6240\u4ee5\u5bf9\u5e94CTLA-4</p> <ol> <li>Basiliximab, daclizumab</li> </ol> <p>Monoclonal antibody; blocks IL-2R</p> <p>B\u662f\u7b2c\u4e8c\u4e2a\u5b57\u6bcd\uff0c\u5bf9\u5e94IL-2R</p> <p>28.Erenumab, fremanezumab and galcanezumab \u6765\u81eaIshmael</p> <p>anti-CGRP monoclonal antibodies</p> <p>era\uff08\u7eaa\u5143\uff09+num\uff08\u6570\u76ee\uff09\uff1bframe\uff08\u753b\u6846\uff09\uff1bgal\uff08girl\uff09+cane\uff08\u62c4\u62d0\uff09\uff1b\u8bb0\u5fc6\u753b\u9762\uff1a\u5728\u4e00\u4e2a\u5e74\u4ee3\u4e45\u8fdc\u7684\u753b\u6846\u91cc\u9762\u6709\u5e45\u753b\uff1a\u4e00\u4e2a\u6709migraine\u7684\u5973\u5b69\u56e0\u5934\u75bc\u62c4\u7740\u62d0\u6756</p>"}, {"location": "USMLE/Blood/", "title": "Myeloproliferative neoplasms", "text": ""}, {"location": "USMLE/Blood/#myeloproliferative-neoplasms", "title": "Myeloproliferative neoplasms", "text": "<p>Myeloproliferative neoplasms (MPNs) were previously referred to as myeloproliferative diseases until 2008 when they were reclassified as cancers. The difference between MPD and MDS is whether the cells mature normally or abnormally. In myeloproliferative disorders, cells mature normally, but they have an abnormally high amount of proliferation. In myelodysplastic syndromes, the cells mature abnormally. A stem cell in the bone marrow, instead of maturing into a normal cell, matures into something else \u2013 something just weird, and often not very functional.</p>"}, {"location": "USMLE/Blood/Alkaline%20phosphatase/", "title": "Alkaline phosphatase", "text": "<p>A group of enzymes found throughout the body but produced predominantly in the liver, bones, placenta, and small intestine. Common causes of elevated serum ALP include cholestasis, bone disease (e.g., bone metastases, Paget\u2019s disease, hyperparathyroidism), and pregnancy. The normal reference range is 20\u201370 U/L.</p>"}, {"location": "USMLE/Blood/Anemia/", "title": "Aplastic anemia", "text": ""}, {"location": "USMLE/Blood/Anemia/#aplastic-anemia", "title": "Aplastic anemia", "text": "<ul> <li>Description<ul> <li>Pancytopenia\u2003caused by\u2003bone marrow insufficiency\u2003[20]</li> <li>Should not be confused with\u2003aplastic crisis, a condition in which\u2003erythropoiesis\u2003is temporarily suppressed (e.g., due to\u2003parvovirus B19\u2003infection in patients with\u2003hemolytic anemias)</li> </ul> </li> <li>Etiology<ul> <li>Idiopathic\u2003in\u2003&gt; 50%\u2003of cases<ul> <li>Could be telomerase deficient</li> <li>Possibly\u2003immune-mediated</li> <li>May follow acute\u2003hepatitis\u2003(hepatitis-associated\u2003aplastic anemia)</li> </ul> </li> <li>Medication side effects:\u2003carbamazepine,\u2003methimazole,\u2003NSAIDs,\u2003chloramphenicol,\u2003propylthiouracil,\u2003sulfa drugs, cytostatic\u2003drugs\u2003(esp.\u2003alkylating agents\u2003and\u2003antimetabolites)\u2003</li> <li>Toxins:\u2003benzene, cleaning solvents, insecticides,\u2003toluene</li> <li>Ionizing radiation</li> <li>Viruses:\u2003HBV,\u2003EBV,\u2003CMV,\u2003HIV</li> <li>Fanconi anemia\u2003\u2003[21][22]<ul> <li>Hereditary\u2003autosomal recessive\u2003disorder\u2003due to a\u2003DNA crosslink\u2003repair defect\u2003resulting in\u2003bone marrow\u2003failure</li> <li>Skeletal and organ abnormalities:\u2003short stature, hypo- and\u2003hyperpigmentation,\u2003cafe-au-lait spots,\u2003microcephaly,\u2003developmental delay,\u2003thumb and forearm\u2003malformations,\u2003kidney, GI,\u2003heart,\u2003eye, and\u2003ear\u2003abnormalities</li> <li>Laboratory tests show\u2003pancytopenia\u2003and\u2003normocytic\u2003or\u2003macrocytic anemia.</li> <li>\u223c 50%\u2003of patients with\u2003Fanconi anemia\u2003will develop\u2003acute myeloid leukemia\u2003or\u2003myelodysplastic syndromes\u2003in early adulthood.\u2003[23]</li> </ul> </li> </ul> </li> <li>Clinical features<ul> <li>Fatigue,\u2003malaise</li> <li>Pallor</li> <li>Purpura,\u2003petechiae,\u2003mucosal\u2003bleeding</li> <li>Infection</li> </ul> </li> <li>Diagnostics<ul> <li>CBC:<ul> <li>Pancytopenia\u2003(in contrast to\u2003aplastic crisis\u2003characterized by anemia only)</li> <li>Normocytic\u2003or\u2003macrocytic anemia</li> </ul> </li> <li>Reticulocyte count: low</li> <li>EPO\u2003level: high</li> <li>Bone marrow biopsy\u2003findings<ul> <li>Hypocellular\u2003fat-filled\u2003marrow (dry bone marrow tap)\u2003</li> <li>RBCs\u2003normal morphology</li> </ul> </li> </ul> </li> <li>Treatment<ul> <li>Cessation of the causative agent</li> <li>Supportive therapy<ul> <li>Treatment of infections</li> <li>Blood transfusion</li> <li>Platelet transfusion</li> </ul> </li> <li>Bone marrow\u2003stimulants (e.g.,\u2003GM-CSF,\u2003eltrombopag)</li> <li>Immunosuppressive therapy <ul> <li>Cyclosporine</li> <li>Antithymocyte globulin (ATG)</li> <li>Tacrolimus</li> <li>Alemtuzumab </li> </ul> </li> <li>Consider\u2003hematopoietic cell transplantation\u2003(HCT) in young patients.\u2003[24]</li> </ul> </li> </ul>"}, {"location": "USMLE/Blood/Anticoagulants/", "title": "physiologic anticoagulants", "text": ""}, {"location": "USMLE/Blood/Anticoagulants/#physiologic-anticoagulants", "title": "physiologic anticoagulants", "text": "<ul> <li>Inhibit intrinsic pathway: <ul> <li>Antithrombin (with heparin): inhibit factor 2(thrombin), 9, 10, 11, 12</li> <li>Protein C: inhibit 5, 8; need VitK to synthesize</li> </ul> </li> <li>Inhibit extrinsic pathway:<ul> <li>TFPI(Tissue factor pathway inhibitor): combine factor 10 to inhibit factor 8</li> </ul> </li> </ul>"}, {"location": "USMLE/Blood/Autoimmune%20hemolytic%20anemia/", "title": "Autoimmune hemolytic anemia", "text": "<p>In warm AIHA - we have IgG which is much better fits for splenic macrophage FC receptor - so it causes more extravascular hemolysis. <p>In cold AIHA IgM is much better activates complement in the blood - intravascular hemolysis.</p> <p>But basically they all cause some degree of both intra and extravascular hemolysis</p> <p>If it\u2019s cold- stay inside If it\u2019s warm- go outside &amp; play</p>"}, {"location": "USMLE/Blood/Erythrocyte%20morphology%20and%20hemoglobin/", "title": "Bohr effect", "text": ""}, {"location": "USMLE/Blood/Erythrocyte%20morphology%20and%20hemoglobin/#bohr-effect", "title": "Bohr effect", "text": "<p>The O2 affinity of Hb is inversely proportional to the CO2 content and H+ concentration of blood. High CO2 and H+ concentrations (from tissue metabolism) cause decreased affinity for O2 \u2192 O2 that is bound to Hb is released to tissue (the O2-Hb dissociation curve is shifted to the right). HbO2 + H+ \u21c4 H+Hb + O2 HbO2 + CO2 \u21c4 Hb-COO- + H+ + O2</p>"}, {"location": "USMLE/Blood/Erythrocyte%20morphology%20and%20hemoglobin/#haldane-effect", "title": "Haldane effect", "text": "<p>The CO2 affinity of Hb is inversely proportional to the oxygenation of Hb. When Hb is deoxygenated (typically in peripheral tissue), uptake of CO2 is facilitated. When Hb is oxygenated (in high pO2, for example, in the lungs): Oxygenated Hb has a decreased affinity for CO2 \u2192 CO2 that is bound to Hb is released in the pulmonary arteries to diffuse into the alveoli (the O2-Hb dissociation curve is shifted to the left). Hb releases bound H+ \u2192 \u2191 H+ shifts equilibrium to CO2 production (see equation above) \u2192 CO2 is exhaled in lungs Bohr for body, HaLdane for lung.</p>"}, {"location": "USMLE/Blood/Hemophilia/", "title": "Etiology", "text": ""}, {"location": "USMLE/Blood/Hemophilia/#etiology", "title": "Etiology", "text": "<p>Hemophilia usually affects males, as it is primarily an X-linked recessive disease.</p> <ul> <li>Hemophilia A (factor VIII deficiency): \u223c 80% of cases</li> <li>Hemophilia B (factor IX deficiency): \u223c 20% of cases</li> <li>Hemophilia C (factor XI deficiency): very rare</li> </ul>"}, {"location": "USMLE/Blood/Hemophilia/#clinical-features", "title": "Clinical features", "text": "<ol> <li>Repeated hemarthrosis (e.g., knee joint) \u2192 hemophilic arthropathy (i.e., destruction of the joint due to repeated hemarthrosis)</li> <li>Oral mucosa bleeding, epistaxis, excessive bleeding following small procedures (e.g., dentist procedures)</li> <li>Hemophilia C does not typically manifest with spontaneous bleeding, hemarthrosis, or deep tissue bleeding.</li> </ol>"}, {"location": "USMLE/Blood/Immune%20thrombocytopenia%20%28ITP%29/", "title": "Immune thrombocytopenia (ITP)", "text": ""}, {"location": "USMLE/Blood/Immune%20thrombocytopenia%20%28ITP%29/#etiology", "title": "Etiology", "text": "<ul> <li>Primary ITP: idiopathic (most common)  [6]</li> <li>Secondary ITP associated with:<ul> <li>Autoimmune disorders: SLE, antiphospholipid syndrome</li> <li>Malignancy: lymphoma, leukemia (particularly CLL)</li> <li>Infection: HIV, HCV</li> <li>Drugs: e.g., quinine, beta-lactam antibiotics, carbamazepine, heparin, vaccines, linezolid, sulfonamides, vancomycin, TMP-SMX, antiepileptics  [7]</li> </ul> </li> </ul> <p>The acute form is typically seen in children after a viral disease.</p>"}, {"location": "USMLE/Blood/Immune%20thrombocytopenia%20%28ITP%29/#pathophysiology", "title": "Pathophysiology", "text": "<p>Antiplatelet antibodies (mostly IgG directed against, e.g., GpIIb/IIIa, GpIb/IX) bind to surface proteins on platelets \u2192 sequestration by spleen and liver \u2192 \u2193 platelet count \u2192 bone marrow megakaryocytes and platelet production increase in response (in most cases).</p>"}, {"location": "USMLE/Blood/Immune%20thrombocytopenia%20%28ITP%29/#clinical-features", "title": "Clinical features", "text": "<p>Mostly asymptomatic. Splenomegaly\u2003is very unusual in ITP and makes other diagnoses more likely! </p>"}, {"location": "USMLE/Blood/Jaundice%20and%20cholestasis/", "title": "Jaundice and cholestasis", "text": "<p>The most common causes of adult hyperbilirubinemia can be remembered with the mnemonic \u201cHOT Liver\u201d: Hemolysis, Obstruction, Tumor, and Liver disease.</p>"}, {"location": "USMLE/Blood/Leukocyte%20alkaline%20phosphatase/", "title": "Leukocyte alkaline phosphatase", "text": "<p>An enzyme found in mature leukocytes. Staining of LAP on peripheral blood smear is used to calculate the LAP score. A high LAP score is associated with an increased number of mature white blood cells (e.g., from leukemoid reaction or myeloproliferative disorders); a low LAP score is associated with an increased number of immature white blood cells (e.g., from CML).</p> <p>Differ from Alkaline phosphatase.</p>"}, {"location": "USMLE/Blood/Macrocytic%20anemias/", "title": "VitB12 deficiency", "text": ""}, {"location": "USMLE/Blood/Macrocytic%20anemias/#vitb12-deficiency", "title": "VitB12 deficiency", "text": "<p>In neurologic symptoms caused by vitamin B12 deficiency, both homocysteine and methylmalonic acid levels are increased. Measurement of these metabolites has been shown to be more sensitive in diagnosing vitamin B12 deficiency than measuring serum B12 levels alone [3]. Elevated methylmalonic acid levels indicate a deficiency in vitamin B12, as methylmalonic acid reacts with vitamin B12 to produce coenzyme A, which is essential for normal cellular function [4]. Homocysteine levels also increase due to vitamin B12 deficiency, as vitamin B12 is necessary for the metabolism of homocysteine [4]. These metabolites can serve as early markers for tissue vitamin B12 deficiency, even before hematologic manifestations occur [3].</p>"}, {"location": "USMLE/Blood/Nucleated%20red%20blood%20cells/", "title": "Nucleated red blood cells", "text": "<p>Nucleated red blood cells (NRBCs) are immature red blood cells not normally seen in the peripheral blood beyond the neonatal period. NRBCs provide a measure of erythropoietic activity. Increased NRBCs can occur during acute haemolytic episodes and severe hypoxic stress, or as a result of a haematological malignancy.</p>"}, {"location": "USMLE/Blood/Splenomegaly/", "title": "Etiology", "text": ""}, {"location": "USMLE/Blood/Splenomegaly/#etiology", "title": "Etiology", "text": ""}, {"location": "USMLE/Blood/Thrombotic%20thrombocytopenic%20purpura%20%28TTP%29/", "title": "Etiology", "text": ""}, {"location": "USMLE/Blood/Thrombotic%20thrombocytopenic%20purpura%20%28TTP%29/#etiology", "title": "Etiology", "text": "<p>ADAMTS13 deficiency</p>"}, {"location": "USMLE/Blood/Thrombotic%20thrombocytopenic%20purpura%20%28TTP%29/#pathophysiology", "title": "Pathophysiology", "text": "<p>ADAMTS13 deficiency \u2192 excess vWF \u2192 microthrombus formation \u2192 blockage of small vessels \u2192 RBC fragmentation (hemolysis) and end-organ damage</p>"}, {"location": "USMLE/Blood/Transfusion/", "title": "Transfusion", "text": "<p>Why platelets must be stored in room temperature?</p> <ol> <li>Cold storage can activate platelets: Cold storage of platelets at temperatures below room temperature (15 \u00b0C) can induce platelet activation, resulting in changes in platelet shape and functionality\u20030(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897204/). This activation can lead to platelet aggregation and a decrease in platelet viability, making the stored platelets less effective for transfusion purposes.</li> <li>Platelet clearance from circulation: Platelets stored at refrigerating temperatures are rapidly cleared from the bloodstream when transfused, reducing their effectiveness\u20037(https://pubmed.ncbi.nlm.nih.gov/16232387/). Cold storage can cause clustering of glycoprotein Ib (GPIb) receptors on the platelet surface, which exposes beta-N-acetylglucosamine residues. These exposed residues are recognized by liver macrophages, leading to rapid clearance of the platelets through phagocytosis. This clearance mechanism limits the viability and availability of cold-stored platelets</li> </ol>"}, {"location": "USMLE/Blood/Von%20Willebrand%20disease/", "title": "Von Willebrand disease", "text": "<p>Mixed platelet and coagulation disorders</p>"}, {"location": "USMLE/Blood/Von%20Willebrand%20disease/#epidemiology", "title": "Epidemiology", "text": "<p>Most common congenital bleeding disorder.</p>"}, {"location": "USMLE/Blood/Von%20Willebrand%20disease/#pathophysiology", "title": "Pathophysiology", "text": "<p>Deficiency or dysfunction of vWF leads to:</p> <ul> <li>Dysfunctional platelet adhesion \u2192 impaired primary hemostasis</li> <li>Reduced binding of factor VIII \u2192 increased degradation \u2192 \u2193 factor VIII activity \u2192 impaired intrinsic pathway of secondary hemostasis Ristocetin cofactor assay: measures the ability of von Willebrand factor (vWF) to agglutinate platelets.</li> <li>Ristocetin: antibiotic that activates vWF, which then binds to glycoprotein Ib on platelets </li> <li>Interpretation: If ristocetin is added to blood lacking vWF (or the vWF receptor), platelets will not aggregate.</li> </ul>"}, {"location": "USMLE/Books/The%20Only%20EKG%20book/", "title": "The Only EKG book", "text": "<p>^jabl0dbycnc</p>"}, {"location": "USMLE/Books/Ultrasound/", "title": "Ultrasound", "text": "<p>^56uvyd0t5hx</p>"}, {"location": "USMLE/Cardiology/Acute%20pericarditis/", "title": "Acute pericarditis", "text": "<p>ECG features of pericarditis Not all patients go through all stages and manifestations may vary. In particular, pericarditis due to uremia may not involve characteristic ECG changes. [16] Stage 1: diffuse ST elevations, ST depression in aVR and V1, PR segment depression  Stage 2: ST segment normalizes in \u223c 1 week. Stage 3: inverted T waves Stage 4: ECG returns to normal baseline (as prior to onset of pericarditis) after weeks to months.</p> <p>In contrast to myocardial infarction, pericarditis is characterized by a diffuse distribution of ST elevations on ECG.See also \u201cDifferential diagnoses of ST elevations on ECG.\u201d <ul> <li>First, the diffuseness of the ST elevations (I, II, III, aVF, V3-V6). In myocardial infarction the ST elevations tend to be localized (inferior, anterior, posterior, lateral), often, but not always with reciprocal ST depressions.</li> <li>Second, the PR segment displacement which has been attributed to subepicardial atrial injury. </li> </ul>"}, {"location": "USMLE/Cardiology/Arteriolosclerosis/", "title": "Classifications", "text": "", "tags": ["Arteriolosclerosis"]}, {"location": "USMLE/Cardiology/Arteriolosclerosis/#classifications", "title": "Classifications", "text": "<p>Arteriolosclerosis: hardening of the small arteries and arterioles </p> <ul> <li>Hyaline arteriolosclerosis<ul> <li>Deposition of proteins below the endothelium due to leakage</li> <li>H&amp;E: pink amorphous deposits (hyaline) within the arteriolar walls </li> <li>Causes: chronic essential hypertension, chronic diabetes, and normal aging</li> </ul> </li> <li>Hyperplastic arteriolosclerosis<ul> <li>Proliferation of subendothelial smooth muscle cells in response to very high blood pressure</li> <li>H&amp;E: \u201conion-skin\u201d appearance of the arteriole </li> <li>Cause: malignant hypertension</li> </ul> </li> </ul>", "tags": ["Arteriolosclerosis"]}, {"location": "USMLE/Cardiology/Atrioventricular%20block/", "title": "Mobitz type II [2]", "text": ""}, {"location": "USMLE/Cardiology/Atrioventricular%20block/#mobitz-type-ii-2", "title": "Mobitz type II [2]", "text": ""}, {"location": "USMLE/Cardiology/Atrioventricular%20block/#description", "title": "Description", "text": "<p>Single or intermittent nonconducted P waves without QRS complexes The PR interval remains constant. The conduction of atrial impulses to the ventricles typically follows a regular pattern, e.g.: [2]</p> <ul> <li>3:2 block: regular AV block with 3 atrial depolarizations but only 2 atrial impulses that reach the ventricles (heart rate = \u2154 SA node rate)</li> <li>4:3 block: regular AV block with 4 atrial depolarizations but only 3 atrial impulses that reach the ventricles (heart rate = \u00be SA node rate) While 2:1 block follows a regular pattern, it cannot be classified as Mobitz type I or II and is classified separately (see \u201c2:1 AV block\u201d). [2] Risk of progression to complete heart block: high (&gt; 50%), as it is typically due to infranodal block (usually in the His-Purkinje system) [7] </li> </ul>"}, {"location": "USMLE/Cardiology/Atrioventricular%20block/#21-av-block2", "title": "2:1 AV block\u2003[2]", "text": "<ul> <li>Description<ul> <li>Inhibited conduction of every second atrial\u2003depolarization\u2003(P wave) to the ventricles (heart\u2003rate = \u00bd SA\u2003node rate)</li> <li>Cannot be classified as\u2003Mobitz I\u2003or\u2003Mobitz II\u2003as only one\u2003PR interval\u2003is observed before the subsequent dropped complex\u2003(can fit into both types)</li> <li>Often a transient rhythm occurring on a baseline\u2003Mobitz I\u2003or\u2003Mobitz II\u2003rhythm</li> </ul> </li> <li>Risk of progression to\u2003complete heart block: depends on level of block\u2003<ul> <li>Block at the level of the\u2003AV node\u2003(more common): low</li> <li>Infranodal block\u2003(less common): high   # Ventriculophasic sinus arrhythmia  Sinus rate variation of this type with complete heart block is called ventriculophasic sinus arrhythmia. </li> </ul> </li> </ul>"}, {"location": "USMLE/Cardiology/Cardiac%20transplatation/", "title": "Cardiac transplatation", "text": "<p>Chronic rejection \u2192 acquired transplant vasculopathy \u2192 accelerated coronary artery disease \u2192 angina, low stress tolerance Constitutes the third most common\u2003cause of death\u2003following the first year of\u2003cardiac transplantation\u2003and the most common\u2003cause of death\u2003after the first year. The mechanism of\u2003chronic rejection\u2003is unknown but is thought to involve an immune-mediated process. </p>"}, {"location": "USMLE/Cardiology/Cardiovascular%20examination/", "title": "Jugular venous pressure", "text": ""}, {"location": "USMLE/Cardiology/Cardiovascular%20examination/#jugular-venous-pressure", "title": "Jugular venous pressure", "text": "Wave Description Abnormalities\u2003 a wave The first peak caused by\u2003atrial contraction Absent in\u2003atrial fibrillation c wave The second peak caused by\u2003tricuspid valve\u2003closure, contraction of the\u2003right ventricle, and bulging of the\u2003tricuspid valve\u2003into the\u2003right atrium cv wave\u2003: severe\u2003tricuspid valve regurgitation x descent A drop in\u2003JVP\u2003caused by\u2003atrial relaxation Absent in: Tricuspid valve regurgitation Right heart failure v wave The third peak caused by\u2003venous refilling of the\u2003right atrium\u2003against the closed\u2003tricuspid valve Prominent in: Tricuspid valve regurgitation Right heart failure y descent A drop in\u2003JVP\u2003caused by\u2003decreased\u2003right atrial pressure\u2003as blood flows into the\u2003right ventricle\u2003after opening of the\u2003tricuspid valve\u2003 Prominent in:\u2003[7] Tricuspid valve regurgitation Constrictive pericarditis Absent in: Cardiac tamponade Tricuspid valve stenosis <p> A normal jugular venous pressure (JVP) waveform is composed of:  </p> <ul> <li>a wave: atrial contraction  </li> <li>c wave: tricuspid valve closure  </li> <li>x descent: atrial relaxation  </li> <li>v wave: venous refilling of the atria  </li> <li>y descent: passive filling of right ventricle when the tricuspid valve opens</li> </ul>"}, {"location": "USMLE/Cardiology/Cardiovascular%20examination/#pathology", "title": "Pathology", "text": "<p>Common abnormalities of the JVP waveform include: - Constrictive pericarditis: elevated JVP (due to increased external atrial pressure) with a prominent x (exaggerated atrial relaxation) and y (early rapid ventricular filling) descent - Cardiac tamponade: elevated JVP (due to increased external atrial pressure), a prominent x descent (exaggerated atrial relaxation), and a blunt or absent y descent (minimal ventricular filling) - Tricuspid regurgitation: prominent v wave as the blood from the right ventricle regurgitates into the right atrium during ventricular systole (atrial diastole), increasing interatrial pressure and volume - Tricuspid stenosis: giant a wave due to high right atrial systolic pressure - Atrial septal defect: v wave \u2265 a wave due to the left-to-right shunting of blood - Third-degree atrioventricular (AV) block: cannon a waves due to the loss of AV synchronization and contraction of the atria against a closed tricuspid valve - Atrial fibrillation: absent a waves due to ineffective contraction of the atria</p>"}, {"location": "USMLE/Cardiology/ECGs/", "title": "Tachycardia DDx", "text": ""}, {"location": "USMLE/Cardiology/ECGs/#tachycardia-ddx", "title": "Tachycardia DDx", "text": "<p> The differential diagnosis of a regular narrow tachycardia in general includes 5 major mechanisms: </p> <ul> <li>Sinus tachycardia </li> <li>AVNRT </li> <li>Atrial tachycardia </li> <li>Orthodromic atrio-ventricular reentrant tachycardia (AVRT) involving retrograde conduction over a \u201cconcealed\u201d bypass tract </li> <li>Atrial flutter with 2:1 block</li> </ul>"}, {"location": "USMLE/Cardiology/ECGs/#bradycardia-ddx", "title": "Bradycardia DDx", "text": ""}, {"location": "USMLE/Cardiology/ECGs/#whenever-you-see-a-negative-p-wave-and-qrs-complex-in-lead-i-the-likely-diagnosis-is-limb-lead-reversal", "title": "Whenever you see a negative P wave and QRS complex in lead I the likely diagnosis is limb lead reversal.", "text": ""}, {"location": "USMLE/Cardiology/ECGs/#multifocal-atrial-rhythm", "title": "Multifocal atrial rhythm", "text": "<p> Differentiate from ectopic atrial rhythm. In ectopic atrial rhythm, the P-wave morphology remains consistent as the PACs originate from a single ectopic focus. In contrast, multifocal atrial rhythm shows varying P-wave morphologies from beat to beat, reflecting the random discharge of multiple ectopic atrial foci [4].</p>"}, {"location": "USMLE/Cardiology/ECGs/#early-repolarization", "title": "Early repolarization", "text": "<p> on the LEFT, the T wave repolarization looks like a continuation of the S wave. This is not ST elevation and is seen often in young adults. It is called\u2003benign\u2003early repolarization. On the right, you clearly see the completion of the S wave and a clear ST Segment which allows you to do an accurate ST Elevation measurement.</p>"}, {"location": "USMLE/Cardiology/ECGs/#hyperkalemia", "title": "Hyperkalemia", "text": "\u9ad8\u94be\u8840\u75c7\uff1a\u4e09\u4f4e\u4e00\u9ad8 \u4f4e\u94be\u8840\u75c7\uff1a\u4e09\u9ad8\u4e00\u4f4e \u5174\u594b\u2191\uff08\u2193\uff09 \u5174\u594b\u2191 \u4f20\u5bfc\u2193 \u4f20\u5bfc\u2193 \u81ea\u5f8b\u2193 \u81ea\u5f8b\u2191 \u6536\u7f29\u2193 \u6536\u7f29\u2191\uff08\u2193\uff09 - Mild hyperkalemia:\u20035.5\u20136.4 mEq/L\u2003 - Tall,\u2003peaked\u2003T waves\u2003(\u819c\u5bf9K+\u901a\u900f\u6027\u589e\u8fc7\uff0c\u590d\u6781\u53163\u671f\u52a0\u901f\uff0c\u53cd\u6620\u4e3a3\u671f\u590d\u6781T\u6ce2\u72ed\u7a84\u800c\u9ad8\u8038) - Moderate hyperkalemia:\u20036.5\u20138.0 mEq/L\u2003     - Lengthening\u2003of\u2003QRS interval\u2003(QRS complex\u2003widening) \u2013 because of conduction delay - Widening and\u2003flattening\u2003of\u2003P wave, which eventually disappears\u2003 - Severe hyperkalemia:\u2003&gt; 8.0 mEq/L\u2003 - Absent\u2003P wave - Intraventricular conduction block - Unusual\u2003QRS morphology\u2003\u2003 - Sine wave pattern: a sinusoidal pattern with absent\u2003P waves\u2003and a wide\u2003QRS complex\u2003that merges with the\u2003T wave; a marker of impending\u2003V-Fib\u2003and\u2003asystole - Cardiac arrhythmias\u2003(e.g.,\u2003V-tach,\u2003V-fib),\u2003asystole ##  Hypokalemia - Mild to moderate hypokalemia T-wave flattening  or inversion ST depression Prolonged PR interval - Moderate to severe hypokalemia Presence of U waves: small waveform following the T wave that is often absent but becomes more pronounced in hypokalemia or bradycardia  [2] T and U wave fusion QT prolongation  [13] - Dysrhythmias - Premature atrial and ventricular complexes - Sinus bradycardia - Paroxysmal atrial or junctional tachycardia - Ventricular dysrhythmias, e.g., Torsades de pointes - PEA/asystole To remember that low potassium may result in a flattened T wave, think of: \u201cNo pot, no tea (T)!\u201d ##  Atrioventricular block ##  Bundle Branch Block mnemonic: William Marrow In right bundle branch block, the right precordial leads will show ST-segment depression and T-wave inversion. Similarly, in left bundle branch block, ST-segment depression and T-wave inversion can be seen in the left lateral leads. ##  Mitral stenosis Characteristic findings include: - Left atrial enlargement/P mitrale (widened and biphasic P wave) - Atrial fibrillation - Right ventricular hypertrophy (e.g., right axis deviation, dominant R wave in lead V1) ##  STEMI Timeline of ECG changes in STEMI The sequence of ECG changes over several hours to days: hyperacute T wave \u2192 ST elevation \u2192 pathological Q wave \u2192 T-wave inversion \u2192 ST normalization \u2192 T-wave normalization ###  Pathological Q wave Top: normal Q wave Bottom: pathological Q wave with a duration \u22650.04 s and depth &gt;\u00bc of R wave amplitude (red and green overlays) ##  Miscellaneous ###  P wave Time: &lt; 0.12s = 3 small block Voltage: &lt;0.25mV = 2.5 small block The P wave in V1 is\u2003often biphasic. Early right atrial forces are directed anteriorly, giving rise to an initial positive deflection; these are followed by left atrial forces travelling posteriorly, producing a later negative deflection. In AVNRT, The retrograde P wave (or Atrial echo)\u2003shows up at the end of the QRS. Best observed in lead II or III. Also, Retrograde P wave (aka pseudo-R\u2019 wave) is seen in V1."}, {"location": "USMLE/Cardiology/ECGs/#st-segment", "title": "ST segment", "text": "<p>Time: 0.05-0.15s = 1-3 small block Elevation: \u2265 0.1 mV in a limb lead or \u2265 0.2 mV in a precordial lead. </p>"}, {"location": "USMLE/Cardiology/ECGs/#qt-interval", "title": "QT interval", "text": "<p>The QT interval includes the QRS complex, the ST segment, and the T wave. The two chief causes of a short QT are hypercalcemia and digoxin therapy (associated with characteristic \u201cscooping\u201d of the ST-T complex). A third and relatively rare cause is hereditary short QT (\u201cchannelopathy\u201d-related) that may be associated with ventricular arrhythmia and sudden cardiac arrest. Prolonged QT: Congenital Long QT syndromes, Drug side effects (e.g., antiarrhythmic agents, antidepressants, antipsychotics, phenothiazines, 1st-generation antihistamines, some antibiotics), Electrolyte disturbances (e.g., Hypocalcemia, hypokalemia, hypomagnesemia), Cardiac abnormalities (e.g., inflammatory heart diseases, bradycardia, myocardial ischemia), Arsenic poisoning</p>"}, {"location": "USMLE/Cardiology/ECGs/#rates", "title": "Rates", "text": "<ul> <li>Atrial flutter: 250-300/min \u2013 about 1 small block</li> <li>Atrial fibrillation: 350-400/min \u2013 less than 1 small block</li> <li>Atrial tachycardia, AVNRT: 130-240 \u2013 1-2 small block</li> </ul>"}, {"location": "USMLE/Cardiology/Fibrinous%20pericarditis/", "title": "Fibrinous pericarditis", "text": "<p>Most common cause is uremia\uff08\u5c3f\u6bd2\u75c7\uff09</p>"}, {"location": "USMLE/Cardiology/Hypercalcemia/", "title": "Hypercalcemia", "text": "<p>Hypercalcemia is a total serum calcium concentration of &gt; 10.5 mg/dL (&gt; 2.62 mmol/L) or ionized (free) calcium concentration of &gt; 5.25 mg/dL (&gt; 1.31 mmol/L).</p> <ul> <li>Total protein normal level 6.0 to 8.3 g/dL\u2003(60 to 83 g/L)</li> <li>Albumin normal level 3.4 to 5.4 g/dL\u2003(34 to 54 g/L)</li> <li>Phosphorus normal level 2.5 to 4.5 g/dL\u2003(25 to 45 g/L)</li> </ul>"}, {"location": "USMLE/Cardiology/Hypercalcemia/#causes", "title": "Causes", "text": "<p>PTH-mediated or non-PTH-mediated causes For causes of hypercalcemia, remember \u201cThinking Chimpanzees!\u201d - Thinking: Thiazides, thyroid - Calcium supplementation - Hyperparathyroidism - Immobilization, inherited (FHH) - Milk-alkali synd., meds (thiazides, lithium) - Paraneoplastic PTHrP - Adrenal insufficiency - Neoplasm (multiple myeloma, breast, lung) - Zollinger-Ellison syndrome - Excessive vitamin D - Excessive vitamin A - Sarcoidosis &amp; granulomatous diseases</p>"}, {"location": "USMLE/Cardiology/Hypercalcemia/#clinical-features", "title": "Clinical features", "text": "<p>ECG: Shorten QT interval </p>"}, {"location": "USMLE/Cardiology/Infective%20endocarditis/", "title": "Infective endocarditis", "text": "<p>Bacterial\u2003vegetation \u2192\u2003bacterial thromboemboli\u2003\u2192 vessel\u2003occlusion \u2192\u2003infarctions Emboli\u2003can lead to\u2003metastatic infections\u2003of other organs.</p>"}, {"location": "USMLE/Cardiology/Long%20QT%20syndromes/", "title": "Etiology", "text": ""}, {"location": "USMLE/Cardiology/Long%20QT%20syndromes/#etiology", "title": "Etiology", "text": "<p>The most common form of\u2003congenital LQTS\u2003(LQTS\u2003type 1) is caused by a defect in the slow delayed rectifier voltage-gated\u2003potassium\u2003channel.</p>"}, {"location": "USMLE/Cardiology/Long%20QT%20syndromes/#complications", "title": "Complications", "text": "<ul> <li>Ventricular tachycardia (torsade de pointes)</li> <li>Ventricular fibrillation</li> <li>Asystole</li> <li>Sudden cardiac death</li> </ul>"}, {"location": "USMLE/Cardiology/Rheumatic%20heart%20disease/", "title": "Rheumatic heart disease", "text": "<p>Rheumatic heart disease can affect people of all ages, but it is more common in children and young adults, especially between the ages of 5 and 15 years old. However, it can also develop in adults who have had rheumatic fever as children. The risk of developing rheumatic heart disease is higher in people who have had repeated episodes of rheumatic fever.</p>"}, {"location": "USMLE/Cardiology/Supraventricular%20tachycardia/", "title": "WPW syndrome", "text": ""}, {"location": "USMLE/Cardiology/Supraventricular%20tachycardia/#wpw-syndrome", "title": "WPW syndrome", "text": "<p>WPW syndrome is a specific form of pre-excitation syndrome characterized by a congenital accessory pathway and tachyarrhythmias, while pre-excitation syndrome is a broader term that encompasses various syndromes involving early ventricular activation.</p>"}, {"location": "USMLE/Cardiology/Supraventricular%20tachycardia/#avnrt", "title": "AVNRT", "text": "<p>P wave\u2003is typically not visible\u2003(it falls in or is \u201cburied\u201d in the\u2003QRS complex) Vagal maneuver is the first step to treat AVNRT.</p>"}, {"location": "USMLE/Cardiology/Supraventricular%20tachycardia/#svt-vs-sinus-tachycardia", "title": "SVT vs Sinus tachycardia", "text": "<p>The real difference is the rate, practically. SVT is generally 150 and above. Sinus tach is 100-150.</p>"}, {"location": "USMLE/Cardiology/Thiazides/", "title": "Thiazides", "text": "<p>A group of diuretic agents that act as Na\u207a-Cl\u207b cotransporter inhibitors in the early distal renal tubule. Used mainly to treat hypertension. Examples include hydrochlorothiazide and chlorthalidone. Adverse effects include metabolic alkalosis, electrolyte abnormalities (hypokalemia, hyponatremia, hypomagnesemia, hypercalcemia), metabolic effects (hyperglycemia, hyperuricemia), and sulfonamide hypersensitivity.  </p>"}, {"location": "USMLE/Cardiology/Vagal%20maneuver/", "title": "Vagal maneuver", "text": "<p>A set of actions performed to decrease the heart rate through physical stimulation of the vagus nerve. Common maneuvers are the Valsalva maneuver and carotid massage. The stimulated vagus nerve then acts on the sinoatrial and atrioventricular nodes, which slows the heart rate and reduces conduction velocity.</p>"}, {"location": "USMLE/Cardiology/ectopic%20atrial%20rhythm/", "title": "Ectopic atrial rhythm", "text": "<p>Could be inverted P wave in lead II, which is normally upward.</p>"}, {"location": "USMLE/GI/Absorption/", "title": "Absorption", "text": ""}, {"location": "USMLE/GI/Absorption/#absorption-of-iron-calcium-folate-and-vitb12", "title": "Absorption of Iron, Calcium, Folate, and VitB12", "text": ""}, {"location": "USMLE/GI/Pancreatic%20cancer/", "title": "Clinical features", "text": ""}, {"location": "USMLE/GI/Pancreatic%20cancer/#clinical-features", "title": "Clinical features", "text": ""}, {"location": "USMLE/GI/Pancreatic%20cancer/#hypercoagulability", "title": "Hypercoagulability", "text": "<ul> <li>Trousseau syndrome:\u2003superficial thrombophlebitis\u2003(in 10% of cases)<ul> <li>Recurring\u2003thrombophlebitis\u2003in\u2003changing locations (migratory)</li> <li>Red, tender extremities</li> <li>Classically associated with\u2003pancreatic\u2003cancer</li> </ul> </li> <li>Thrombosis\u2003(e.g.,\u2003phlebothrombosis,\u2003splenic vein thrombosis) A\u2003thrombosis\u2003of unknown origin may be caused by an undiagnosed\u2003malignancy\u2003(especially\u2003pancreatic\u2003cancer, but also pulmonary, and\u2003prostatic carcinoma, the \u201c3P\u2019s\u201c).</li> </ul>"}, {"location": "USMLE/Infective%20disease/Legionnaires%27%20disease/", "title": "Definition", "text": ""}, {"location": "USMLE/Infective%20disease/Legionnaires%27%20disease/#definition", "title": "Definition", "text": "<ul> <li>Legionellosis: an infection caused by Legionella spp.</li> <li>Legionnaires\u2019 disease: a type of legionellosis that manifests as Pneumonia &gt; Atypical pneumonia</li> <li>Pontiac fever: a type of legionellosis that manifests with flu-like symptoms without pneumonia.</li> </ul>"}, {"location": "USMLE/Infective%20disease/Legionnaires%27%20disease/#epidemiology", "title": "Epidemiology", "text": "<ul> <li>Manifests almost exclusively in adults</li> <li>Locations at increased risk of a legionella outbreak include:<ul> <li>Nursing homes</li> <li>Hospitals</li> <li>Confined travel accommodations (e.g., cruise ships, hotels, resorts)</li> </ul> </li> </ul>"}, {"location": "USMLE/Infective%20disease/Legionnaires%27%20disease/#clinical-features", "title": "Clinical features", "text": "<ul> <li>Incubation period: 2\u201310 days</li> <li>Fever, chills, headache</li> <li>Severe atypical pneumonia: dry cough which can become productive, shortness of breath, bilateral crackles</li> <li>Relative bradycardia</li> <li>Diarrhea</li> <li>Neurological features, especially confusion, agitation, and stupor Legionnaires\u2019 disease should always be considered in patients with signs of atypical pneumonia and diarrhea in combination with possible exposure (e.g., cruise ship travel, use of a whirlpool).</li> </ul>"}, {"location": "USMLE/Infective%20disease/Mycobacteria/", "title": "Mycobacteria", "text": "<p> | Pathogen                                             |                         | Reservoir                | Characteristics                                                                                                                                                                                                                  | Virulence factors and resistances                                                                                                                                                                                                                                                                                                                                                                       | Diseases                                                                                                                                                                                           |                                                                                                                                                       | Antibiotic of choice                                                                                                      | | ---------------------------------------------------- | ----------------------- | ------------------------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------- | | Mycobacterium tuberculosis                           |                         | Humans                   | Acid-fast bacilli Ziehl-Neelsen stain   Auramine-rhodamine stain  Gram neutral (do not stain well)  Facultative intracellular Aerobic L\u00f6wenstein-Jensen agar Middlebrook medium Generation time: \u223c12 hours  [63]                 | Cord factor: arranges M. tuberculosis in a serpentine cord \u2192 \u2191 TNF-\u03b1 release and activation of macrophages \u2192 granuloma formation Surface glycolipids: (sulfatides) inhibit phagolysosomal fusion Infiltration of nonactivated macrophages \u2192 escape of humoral immune response  Multi-drug resistance: mutation in KatG (catalase-peroxidase) \u2192 INH conversion to its active metabolite \u2192 INH resistance | Tuberculosis                                                                                                                                                                                       |                                                                                                                                                       | Isoniazid PLUS rifampicin PLUS ethambutol PLUS pyrazinamide See \u201cTuberculosis treatment.\u201d                                 | | Mycobacterium leprae [64]                            |                         | Humans and armadillos    | Acid-fast bacilli: Ziehl-Neelsen stain  Obligate intracellular Generation time: up to 13 days [65]                                                                                                                               | Phenolic glycolipid I (PGL-1) Lipoarabinomannan                                                                                                                                                                                                                                                                                                                                                         | Leprosy                                                                                                                                                                                            |                                                                                                                                                       | Dapsone PLUS rifampicin (tuberculoid leprosy) Clofazimine (add in lepromatous leprosy)                                    | | Nontuberculous mycobacteria M. kansasii, M. ulcerans | M. avium-intracellulare | Ubiquitous               | Acid-fast bacilli: Ziehl-Neelsen stain PCR Generation time: varies among the subtypes (faster than other mycobacteria)                                                                                                           | M. avium-intracellulare are frequently multi-drug resistant                                                                                                                                                                                                                                                                                                                                             | Mycobacterium avium complex infection: disseminated nontuberculous disease mainly in immunocompromised patients (e.g., HIV/AIDS) See \u201cHIV-associated conditions.\u201d                                  | Soft tissue infections with draining sinuses (newly formed channels that lead from the focus of infection to the skin surface via a draining orifice) | Are more drug-resistant than M. tuberculosis Clarithromycin OR azithromycin PLUS rifabutin  (OR rifampin) PLUS ethambutol | |                                                      | M. marinum              |                          |                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                         | Fish tank granuloma: skin infection usually of the hand that occur in individuals handling fish (e.g., aquarium handlers)                                                                          |                                                                                                                                                       |                                                                                                                           | |                                                      | M. scrofulaceum         |                          |                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                         | Cervical lymphadenitis in children                                                                                                                                                                 |                                                                                                                                                       |                                                                                                                           | | Mycoplasma pneumoniae                                |                         | Humans are the only host | Microaerophile Incomplete/absent cell wall (not visible on gram stain)  Bacterial membrane stabilized by cholesterol  Pleomorphic Generation time: (1\u20133 weeks)  [66] M. pneumoniae: grows on Eaton agar \u2192 \u201cfried egg\u201d appearance | Unresponsive to beta-lactam antibiotics due to lacking cell wall                                                                                                                                                                                                                                                                                                                                        | Mycoplasma pneumonia (atypical pneumonia) Cold antibody hemolytic anemia (IgM) Erythema multiforme Acute interstitial nephritis Stevens-Johnson syndrome (affects mostly children and adolescents) |                                                                                                                                                       | Macrolides (e.g., erythromycin) OR doxycycline OR fluoroquinolones                                                        | | Ureaplasma urealyticum                               |                         | Normal urogenital flora  |                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                         | Urocystitis                                                                                                                                                                                        |                                                                                                                                                       | Doxycycline OR macrolides (e.g., erythromycin)                                                                            |</p>"}, {"location": "USMLE/Muscle%2C%20skin%2C%20and%20connective%20tissue/Antiphospholipid%20syndrome/", "title": "Pathophysiology", "text": ""}, {"location": "USMLE/Muscle%2C%20skin%2C%20and%20connective%20tissue/Antiphospholipid%20syndrome/#pathophysiology", "title": "Pathophysiology", "text": "<ul> <li>Formation of procoagulatory antiphospholipid antibodies <ul> <li>Antibodies form complexes with anticoagulant proteins, thereby inactivating them (e.g., protein C, protein S, antithrombin III).</li> <li>Antibodies activate platelets and vascular endothelium. </li> </ul> </li> <li>Induction of a hypercoagulable state \u2192 \u2191 risk of thrombosis and embolism [3]</li> </ul>"}, {"location": "USMLE/Muscle%2C%20skin%2C%20and%20connective%20tissue/Antiphospholipid%20syndrome/#clinical-features", "title": "Clinical features", "text": "<p>APS\u2003usually manifests with\u2003recurring\u2003thrombotic events\u2003that may affect any organ. Pregnancy-related: recurrent miscarriages and premature births.(Caused by\u2003thrombosis\u2003of\u2003placental\u2003vessels and possible subsequent\u2003placental infarction)</p> <p>Thrombosis\u2003in\u2003APS\u2003is typically unprovoked (e.g.,\u2003unprovoked DVT), recurrent, and/or manifests in unusual sites (e.g.,\u2003kidneys,\u2003liver,\u2003retina). It is most commonly seen in younger individuals (&lt; 50 years of age) and in individuals with comorbid autoimmune diseases (e.g.,\u2003SLE).</p>"}, {"location": "USMLE/Muscle%2C%20skin%2C%20and%20connective%20tissue/Antiphospholipid%20syndrome/#diagnose", "title": "Diagnose", "text": "<p>Antiphospholipid antibodies\u2003(aPL antibodies)</p> <ul> <li>Lupus anticoagulant\u2003(LA):\u2003antibodies\u2003against certain phospholipids in\u2003cellular membranes</li> <li>Anticardiolipin antibodies\u2003(IgG\u2003and\u2003IgM)</li> <li>Anti-\u03b22-glycoprotein antibodies\u2003(IgG\u2003and\u2003IgM)</li> </ul>"}, {"location": "USMLE/Muscle%2C%20skin%2C%20and%20connective%20tissue/Myasthenia%20gravis/", "title": "Myasthenia gravis", "text": "<p>Associated with Thymoma.</p>"}, {"location": "USMLE/Muscle%2C%20skin%2C%20and%20connective%20tissue/Myasthenia%20gravis/#pathophysiology", "title": "Pathophysiology", "text": ""}, {"location": "USMLE/Muscle%2C%20skin%2C%20and%20connective%20tissue/Myasthenia%20gravis/#thymusinvolvement", "title": "Thymus\u2003involvement", "text": "<p>Muscle-like\u2003(myoid) cells in the\u2003thymus\u2003express\u2003AChR\u2003\u2192\u2003autoreactive targeting by\u2003T cells\u2003\u2192\u2003production of\u2003acetylcholine receptor antibodies\u2003(AChR antibodies)</p>"}, {"location": "USMLE/Muscle%2C%20skin%2C%20and%20connective%20tissue/Myasthenia%20gravis/#acetylcholine-receptor-antibodies4", "title": "Acetylcholine receptor antibodies\u2003[4]", "text": "<ul> <li>Responsible for inhibition of\u2003signal transduction\u2003at the\u2003neuromuscular junction\u2003(NMJ)</li> <li>Antibodies\u2003target postsynaptic\u2003AChRs\u2003of normal muscle\u2003cells \u2192\u2003competitive inhibition of\u2003acetylcholine\u2003(ACh) \u2192\u2003AChR\u2003decay through\u2003receptor\u2003internalization (\u2193\u2003receptor\u2003density\u2003at the postsynaptic membrane)\u2003and activation of complement (\u2192 muscle cell\u2003lysis) \u2192\u2003impaired\u2003signal transduction\u2003at the\u2003NMJ\u2003\u2192\u2003skeletal muscle\u2003weakness and fatigue\u2003<ul> <li>Seropositive MG (80\u201390%\u2003of cases):\u2003positive assays\u2003for\u2003antibodies\u2003(in blood) against the\u2003acetylcholine receptor\u2003(AChR-Ab)</li> <li>Seronegative MG (10\u201320%\u2003of cases): negative for\u2003AChR antibodies, but may be positive for\u2003muscle-specific tyrosine kinase antibodies\u2003(MuSK antibodies) </li> </ul> </li> </ul>"}, {"location": "USMLE/Muscle%2C%20skin%2C%20and%20connective%20tissue/Thymoma/", "title": "Thymoma", "text": "<p>A tumor of the thymus gland. An asymptomatic thymoma is usually detected as an incidental finding on a chest x-ray, where it appears as a mediastinal mass. Symptomatic thymomas typically present in individuals between 40\u201360 years of age with thoracic symptoms (e.g., chest pain, cough, dyspnea) or paraneoplastic syndromes, the most common of which is myasthenia gravis. Treatment options include surgery, chemotherapy, and/or radiotherapy.</p>"}, {"location": "USMLE/Neurology/Headaches/", "title": "Migraine", "text": ""}, {"location": "USMLE/Neurology/Headaches/#migraine", "title": "Migraine", "text": ""}, {"location": "USMLE/Respiratory/Neonatal%20respiratory%20distress%20syndrome/", "title": "Etiology", "text": ""}, {"location": "USMLE/Respiratory/Neonatal%20respiratory%20distress%20syndrome/#etiology", "title": "Etiology", "text": "<ul> <li>Premature birth</li> <li>Maternal diabetes mellitus: leads to \u2191 fetal insulin, which inhibits surfactant synthesis</li> <li>Hereditary  [1]</li> <li>Cesarean delivery: results in lower levels of fetal glucocorticoids than vaginal delivery, in which higher levels are released as a response to stress from uterine contractions </li> <li>Hydrops fetalis</li> <li>Multifetal pregnancies</li> <li>Male sex</li> </ul>"}, {"location": "USMLE/Respiratory/Pneumonia/", "title": "Clinical features", "text": ""}, {"location": "USMLE/Respiratory/Pneumonia/#clinical-features", "title": "Clinical features", "text": ""}, {"location": "USMLE/Respiratory/Pneumonia/#typical-pneumonia", "title": "Typical pneumonia", "text": "<p>Typical pneumonia is characterized by a sudden onset of symptoms caused by lobar infiltration.</p> <ul> <li>Severe malaise</li> <li>High fever and chills</li> <li>Productive cough with purulent sputum (yellow-greenish)<ul> <li>Crackles and bronchial breath sounds on auscultation</li> <li>Decreased breath sounds</li> <li>Enhanced bronchophony, egophony, and tactile fremitus</li> <li>Dullness on percussion </li> </ul> </li> <li>Tachypnea and dyspnea (nasal flaring, thoracic retractions) </li> </ul> <p>Suspect bacterial pneumonia in immunocompromised patients with acute high fever and pleural effusion.</p>"}, {"location": "USMLE/Respiratory/Pneumonia/#atypical-pneumonia", "title": "Atypical pneumonia", "text": "<p>Atypical pneumonia typically has an indolent course (slow onset) and commonly manifests with extrapulmonary symptoms.</p> <ul> <li>Nonproductive, dry cough</li> <li>Dyspnea</li> <li>Auscultation often unremarkable</li> <li>Common extrapulmonary features include fatigue, headaches, sore throat, myalgias, and malaise.</li> </ul> <p>This classification does not have a major impact on patient management because it is not always possible to clearly distinguish between typical and atypical pneumonia.</p>"}, {"location": "USMLE/Respiratory/Pneumonia/#pathogen-specific-pneumonia", "title": "Pathogen-specific pneumonia", "text": ""}, {"location": "USMLE/Respiratory/Pneumonia/#mycoplasma-pneumonia", "title": "Mycoplasma pneumonia", "text": ""}, {"location": "USMLE/Respiratory/Pneumonia/#epidemiology", "title": "Epidemiology", "text": "<ul> <li>One of the most common causes of atypical pneumonia</li> <li>More common in school-aged children and adolescents</li> <li>Outbreaks most commonly occur in schools, colleges, prisons, and military facilities.</li> </ul>"}, {"location": "USMLE/Respiratory/Pneumonia/#clinical-features_1", "title": "Clinical features", "text": "<ul> <li>Generalized papular rash</li> <li>Erythema multiforme </li> <li>Pneumonia &gt; Atypical pneumonia</li> </ul>"}, {"location": "USMLE/Respiratory/Pneumonia/#diagnostics", "title": "Diagnostics", "text": "<ul> <li>Subclinical hemolytic anemia: associated with elevated cold agglutinin titers (IgM)</li> <li>Interstitial pneumonia, often with a reticulonodular pattern on chest x-ray</li> <li>Chest x-ray can show extensive pulmonary involvement in patients with mild pneumonia.</li> </ul>"}, {"location": "USMLE/Respiratory/Pulmonary%20embolism/", "title": "ECG", "text": ""}, {"location": "USMLE/Respiratory/Pulmonary%20embolism/#ecg", "title": "ECG", "text": "<p>ECG changes may be due to right ventricular strain and pressure overload. Most common findings </p> <ul> <li>T-wave inversions or flattening</li> <li>Sinus tachycardia </li> <li>Normal ECG Predictors of adverse outcomes: See \u201cHigh-risk ECG findings in PE.\u201d Other ECG findings in PE: sinus bradycardia (&lt; 60/min); uncommon) </li> </ul>"}, {"location": "USMLE/Ultrasound/", "title": "Transducer types", "text": ""}, {"location": "USMLE/Ultrasound/#transducer-types", "title": "Transducer types", "text": "<p>phased array, curvilinear (curved, convex) array, linear array </p>"}, {"location": "USMLE/Ultrasound/#hyperechoic-and-hypoechoic", "title": "Hyperechoic and hypoechoic", "text": "<ul> <li>Hypoechoic masses are solid masses of dense tissue that appear dark gray on the ultrasound image. They can be cancerous.\u2003</li> <li>Hyperechoic masses bounce back many sound waves and appear as light gray on the ultrasound. They are not as dense as hypoechoic masses and may contain air, stone, bone, fat, or fluid. Hyperechoic masses are rarely cancerous.</li> </ul>"}, {"location": "tags/", "title": "Tags", "text": ""}, {"location": "tags/#arteriolosclerosis", "title": "Arteriolosclerosis", "text": "<ul> <li>Classifications</li> </ul>"}]}